Login to Your Account

Brivanib gets a second chance for China's many liver cancer patients

By Shannon Ellis
Staff Writer

Monday, March 23, 2015

SHANGHAI – Brivanib, an oral kinase inhibitor for liver cancer, is getting another crack at getting on the market, and this time, if successful, it will be in China where almost half the world's liver cancer patients reside.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription